HomeAI · summaries
Storia in 6 fonti
FDA approves Vera’s dual-target Trutakna, setting up IgAN market battle with Novartis, Otsuka
When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no FDA-approved treatment options. | When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no FDA-approved treatment options. Today, the dual-target drug has crossed the regulatory finish line but is entering a vastly different landscape as the sixth drug approved for the rare kidney disease.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
benzinga.com
What's Going on with Vera Therapeutics Stock on Monday? - Vera Therapeutics (NASDAQ:VERA)
Vera Therapeutics awaits the FDA's July 7 decision on atacicept for IgA nephropathy as investors weigh trial data and competition from Novartis.
- ·
healio.com
FDA approves Trutakna for proteinuria reduction in IgA nephropathy
The FDA granted accelerated approval to atacicept-vymj for proteinuria reduction in adults with primary immunoglobulin A nephropathy at risk for disease progression, according to…
